BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of diseases that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression. This is a large paradigm shift from today’s symptom-oriented therapies.
BioArctic’s proprietary technology platform, dedicated personnel, collaborations with leading academic research groups and the global pharma industry have made it possible to develop innovative treatments based on antibodies (immunotherapy) for neurodegenerative diseases and a potential treatment for complete Spinal Cord Injuries.
Our main research areas are Alzheimer’s disease and Parkinson’s disease where there are large unmet medical needs. Today there are no treatments that can stop or slow down the progression of these diseases. We are also developing a potential treatment for patients affected by complete Spinal Cord Injury and for whom no treatment is currently available.
BioArctic’s laboratories and headquarters are located in central Stockholm, Sweden, where approximately 40 employees and consultants are working. In order to conduct efficient operations with a relatively small organization, BioArctic engages key consultants for specific assignments and for tasks in competence areas that the company lacks or only has periodic need for.
We also collaborate with research groups at universities and hospitals, and with our global research and development partners Eisai and AbbVie.
BioArctic contracts also external companies to a large extent for pharmacology, toxicology studies, process development, the manufacturing of drug substances and the performance of clinical trials.
Neurodegenerative diseases are diseases where nerve cells in the brain break down and die. These cells cannot be reformed, thus the damages to the nervous system is devastating.
The neurodegenerative process usually starts long before any obvious signs are present, but eventually results in impairment and disability. These diseases have a profound impact on the lives of millions of people worldwide.
BioArctic is a Swedish research oriented biopharma company. The company was founded in 2003 by Professor Lars Lannfelt and Dr. Pär Gellerfors to develop important breakthrough discoveries made by Professor Lannfelt regarding Alzheimer’s disease. These discoveries – the Swedish mutation and the Arctic mutation – have attracted much attention internationally and explain the central role of amyloid-beta in Alzheimer’s disease, which has led to the development of new treatment strategies.
BioArctic has developed a proprietary technology platform that has proven to be successful when the company’s first drug candidate antibody BAN2401 for Alzheimer´s disease was developed.
The company’s technology is now also used for other diseases of the Central Nervous System such as Parkinson’s disease (BioArctic’s antibody BAN0805) and also for related diagnostics and technology.
Strengths and success factors
BioArctic´s success is built on vast scientific competence and highly skilled employees who thrive and deliver with great quality.
At BioArctic we are proud of our strengths, which we consider to be important success factors in our ambition to improve the quality of life for patients with diseases affecting the Central Nervous System.
BioArctic’s strengths include:
- Highly qualified staff with proven ability to develop drugs
- An innovative project portfolio consisting of differentiated first generation disease modifying drug candidates for neurodegenerative diseases, related diagnostics and technology and a new treatment concept for complete Spinal Cord Injury
- Strategic collaborations and partnerships with the global pharma companies Eisai and AbbVie and funding from the EU’s Horizon2020 that validate the ability of the research organization and the potential of the drug candidates
- An attractive combination of fully financed partner projects with significant market potential and innovative in-house projects with significant outlicensing potential
- A strong intellectual property rights portfolio.